Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Effect of single mutations on IN sensitivity to clinically tested inhibitors.

From: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Mutation S-1360 L870, 810 MK-0518 GS-9137 GSK-364735
T66I ++ + ++ +++ +
L68V    + +  
L68I    + +  
V72I   +   ++  
L74M ++++ + + ++  
E92Q ++ + ++ +++ ++
Q95K   ++   ++  
F121Y +++ ++ ++ +++ +++
T124A +     +
T125K   + + +  
E138K + + + +  
G140S ++   + ++  
P145S ++     +
Q146R ++ +   +++ +
S147G   ++ + ++  
Q148H +++   +++ ++  
Q148R ++++   +++ +++++ ++++
Q148K ++++   +++ ++++ +++++
V15II   +++ + ++  
S153Y ++   + ++ +
N155H ++   +++ +++  
N155S +++ ++ ++   +++
E157Q     ++  
R263K     ++  
E92Q/N155H    ++++ ++++  
F121Y/T125K    ++ ++++  
G140S/Q148H    +++++ +++++  
V72I/F121Y/T125K/V151I   +++++   +++++  
  1. Fold change in potency compared to wild type: + <2, ++ 2–10, +++ 11–50, ++++ 51–100, +++++ >100